生物制剂治疗与类风湿关节炎骨丢失
本文综述2003至2015年文献,评估生物制剂对类风湿关节炎患者骨密度、骨转换标志物及脆性骨折的影响。抗TNF阻断剂研究显示脊柱和髋部骨密度保持或增加,骨标志物谱更优;IL-6阻断剂改善局部骨丢失;利妥昔单抗和阿巴西普研究较少。骨折风险研究仍不足。
要点
- 抗TNF阻断剂与脊柱和髋部骨密度保持或增加相关,骨标志物谱更优。
- IL-6阻断剂显示抗TNF药物未见到的局部骨丢失改善。
- 仅三项流行病学研究分析抗TNF阻断剂治疗后的骨折影响。
核心结论
- 生物制剂治疗与骨丢失减少相关。
- 抗TNF阻断剂研究显示脊柱和髋部骨密度保持或增加,骨标志物谱更优,多数研究使用英夫利西单抗。
- IL-6阻断剂显示抗TNF药物未见到的局部骨丢失改善,利妥昔单抗和阿巴西普研究较少。
- 尽管多项研究报告生物制剂对骨保护有利作用,关于其骨折风险作用的研究仍有未满足需求。
研究设计与样本
- 采用PICOST方法,由两位共同作者检索Medline和Science Direct数据库2003至2015年英文成人原始研究。
- 初检904条标题,筛选253条,研究者间选择一致性Kappa统计量为0.95(p<0.000),仅248篇摘要纳入PICOST评估。
- 系统检索最终纳入28项研究,并手工检索所选文章参考文献补充纳入正文及「新型药物小分子」部分。
主要发现
- 抗TNF阻断剂研究显示脊柱和髋部骨密度保持或增加,骨标志物谱更优,多数研究使用英夫利西单抗。
- 仅三项流行病学研究分析抗TNF阻断剂治疗后的骨折影响。
- IL-6阻断剂显示抗TNF药物未见到的局部骨丢失改善。
- 利妥昔单抗和阿巴西普研究较少。
局限性
- 关于生物制剂对骨折风险作用的研究仍有未满足需求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Rheumatoid arthritis (RA) is a common systemic autoimmune disease of unknown cause, characterized by a chronic, symmetric, and progressive inflammatory polyarthritis. One of the most deleterious effects induced by the chronic inflammation of RA is bone loss. During the last 15 years, the better knowledge of the cytokine network involved in RA allowed the development of potent inhibitors of the inflammatory process classified as biological DMARDs. These new drugs are very effective in the inhibition of inflammation, but there are only few studies regarding their role in bone protection. The principal aim of this review was to show the evidence of the principal biologic therapies and bone loss in RA, focusing on their effects on bone mineral density, bone turnover markers, and fragility fractures. METHODS: Using the PICOST methodology, two coauthors (PC, LM-S) conducted the search using the following MESH terms: rheumatoid arthritis, osteoporosis, clinical trials, TNF- antagonists, infliximab, adalimumab, etanercept, certolizumab, golimumab, IL-6 antagonists, IL-1 antagonists, abatacept, tocilizumab, rituximab, bone mineral density, bone markers, and fractures. The search was conducted electronically and manually from the following databases: Medline and Science Direct. The search period included articles from 2003 to 2015. The selection included only original adult human research written in English. Titles were retrieved and the same two authors independently selected the relevant studies for a full text. The retrieved selected studies were also reviewed completing the search for relevant articles. The first search included 904 titles from which 253 titles were selected. The agreement on the selection among researchers resulted in a Kappa statistic of 0.95 (p < 0.000). Only 248 abstracts evaluated were included in the acronym PICOST. The final selection included only 28 studies, derived from the systematic search. Additionally, a manual search in the bibliography of the selected articles was made and included into the text and into the section of "small molecules of new agents." CONCLUSION: Treatment with biologic drugs is associated with the decrease in bone loss. Studies with anti-TNF blocking agents show preservation or increase in spine and hip BMD and also a better profile of bone markers. Most of these studies were performed with infliximab. Only three epidemiological studies analyzed the effect on fractures after anti-TNF blocking agent's treatment. IL-6 blocking agents also showed improvement in localized bone loss not seen with anti-TNF agents. There are a few studies with rituximab and abatacept. Although several studies reported favorable actions of biologic therapies on bone protection, there are still unmet needs for studies regarding their actions on the risk of bone fractures.
引用
- Zerbini CAF, Clark P, Mendez-Sanchez L, et al. Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int. 2016. PMID: 27796445. doi:10.1007/s00198-016-3769-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。